Edwards Lifesciences (NYSE:EW) won an investigational device exemption from the FDA to begin a clinical trial of its Edwards Intuity heart valve.
The device maker’s Transform trial is the 1st of its kind in the U.S. for a rapid deployment system for surgical aortic valve replacement, according to a press release.